Three analysts set PLN 86.83 target for Captor Therapeutics stock

Investing.com listed a 12-month consensus target of PLN 86.83 from three analysts on October 6, 2026. That target stood 48.68 percent above Captor Therapeutics at PLN 58.40 on the Warsaw Stock Exchange, using the same-currency Polish quotation. At Lang & Schwarz, the euro quotation was EUR 13.36 on October 15, 2026 at 10:57 p.m. CEST, while the Warsaw session ended 2.01 percent lower.

First-half loss widens 11.18 percent

The latest published accounts showed a larger loss but also a stronger equity base. According to Bankier.pl, Captor reported a PLN 22.762 million net loss for the first half of 2026, compared with PLN 20.474 million in the first half of 2025. Research and development revenue fell to PLN 1.962 million from PLN 4.616 million over the same periods, while equity reached PLN 65.065 million on June 30, 2026.

Stock sits below its yearly high

The Warsaw quotation remained 34.53 percent below its 52-week high of PLN 89.20 and 48.47 percent above its 52-week low of PLN 39.30 on October 15, 2026. Captor's market capitalization was PLN 369.9 million, with a negative P/E ratio of -7.42 and volume of 26,322 shares. The company is a biotechnology business developing targeted protein degradation treatments.

Valuation and November results date

The next scheduled reporting date is November 19, 2026. Zonebourse lists that date for the publication of third-quarter results. The calendar gives investors a defined point for comparing cash use, revenue and the development pipeline with the first-half figures.

Comparison with peers

Captor Therapeutics (Warsaw, PLN): minus 2.01 percent, P/E -7.42, market capitalization PLN 369.9 million
Ryvu Therapeutics (Warsaw, PLN): plus 3.20 percent, P/E -5.79, market capitalization PLN 403.2 million
Molecure (Warsaw, PLN): minus 0.31 percent, P/E -9.95, market capitalization PLN 157.2 million

Price remains below the yearly high

The euro quotation places Captor Therapeutics below its Warsaw 52-week high, while the scheduled November report offers the next dated checkpoint for operating figures. The stock was trading at EUR 13.36 at Lang & Schwarz on October 15, 2026 at 10:57 p.m. CEST, and the Warsaw session was down 2.01 percent on the day.

The further course of trading is shown by the continuously updated real-time quote of Captor Therapeutics stock.

Market context: Market report WIG 20.

More news and analyses on Captor Therapeutics stock